在非小细胞肺癌(NSCLC)中,KRAS G12C是最常见的KRAS突变亚型,约占非鳞状NSCLC的12%~14%。尽管第一代KRAS G12C抑制剂(如索托拉西布和阿达格拉西布)已获批用于经治患者,但其临床获益相对有限,且耐药问题难以避免,临床上亟需更高效的治疗手段。
编者按:在非小细胞肺癌(NSCLC)中,KRAS G12C是最常见的KRAS突变亚型,约占非鳞状NSCLC的12%~14%。尽管第一代KRAS G12C抑制剂(如索托拉西布和阿达格拉西布)已获批用于经治患者,但其临床获益相对有限,且耐药问题难以避免,临床上亟需更高效的治疗手段。
在2026年欧洲肿瘤内科学会(ESMO)大会上,由德克萨斯大学MD安德森癌症中心Ferdinandos Skoulidis教授团队牵头开展的全球、随机、开放标签III期Krascendo 1研究(LBA5)重磅公布。该研究评估了新一代口服KRAS G12C(OFF)抑制剂Divarasib对比索托拉西布或阿达格拉西布,在经治晚期/转移性KRAS G12C突变NSCLC患者中的疗效与安全性。会议现场,《肿瘤瞭望》特邀美国MD安德森癌症中心Ferdinandos Skoulidis教授接受专访,深度解读该研究的核心数据,并探讨KRAS靶向治疗的耐药机制与未来方向。
《肿瘤瞭望》:请您分享Krascendo 1研究的主要疗效与安全性数据。您如何评价Divarasib在经治KRAS G12C突变NSCLC中的整体表现?
Ferdinandos Skoulidis教授:Krascendo 1是一项全球、随机、开放标签的III期临床研究,旨在评估新一代口服KRAS G12C(OFF)抑制剂Divarasib对比第一代抑制剂索托拉西布或阿达格拉西布,在既往接受过治疗的晚期/转移性KRAS G12C突变NSCLC患者中的疗效与安全性。研究共纳入338例既往接受过含铂化疗及程序性死亡受体1/配体1(PD-1/PD-L1)抑制剂(1-3线)的患者,按1:1随机分组,主要终点为盲态独立中心审查(BICR)评估的无进展生存期(PFS)。
研究成功达到了其主要终点。在BICR评估的PFS方面,Divarasib较对照组展现出了具有统计学显著性和临床意义的改善。 Divarasib组的中位PFS为9.8个月,对照组为5.7个月,疾病进展或死亡风险显著降低42%(HR 0.58),实现了4.1个月的绝对延长。
更为关键的是,在首次预设的期中总生存期(OS)分析中,Divarasib也达到了关键次要终点。 其显著延长了OS,中位OS为17.7个月,对照组仅为12.0个月(HR 0.56),死亡风险降低了44%,中位OS绝对延长达5.7个月。此外,Divarasib组的BICR确认客观缓解率(ORR)达到了58%,远高于对照组的32%。
在安全性方面,Divarasib表现出可管理且在多维度上更优的安全性特征。 与对照组相比,Divarasib组发生的≥3级治疗相关不良事件(TRAE)更少,严重不良事件发生率也更低。这直接反映在更低的因TRAE导致的停药率上:Divarasib组仅为4.8%,而对照组高达11.7%。综合来看,Krascendo 1研究实现了PFS、OS及ORR的全面获益,基于这一完整的数据集,Divarasib已确立了其在经治晚期KRAS G12C突变NSCLC中的新标准治疗地位。
Oncology Frontier: Would you please share the primary efficacy and safety findings, and your overall evaluation of divarasib for previously treated KRAS G12C-mutant non-small cell lung cancer (NSCLC)?
Prof. Ferdinandos Skoulidis: So the Krascendo 1 clinical trial met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in progression-free survival (PFS) by blinded independent central review (BICR) with divarasib compared with sotorasib or adagrasib, with a hazard ratio (HR) of 0.58. In other words, a 42% reduction in the risk of disease progression or death. The median PFS with divarasib was 9.8 months compared with 5.7 months with sotorasib or adagrasib. So, a 4.1-month absolute improvement in median PFS.
But critically, the Krascendo 1 clinical trial also met its key secondary endpoint of overall survival (OS) at the time of the first interim OS analysis. Divarasib significantly prolonged OS compared with sotorasib or adagrasib, with an HR of 0.56. In other words, a 44% reduction in the risk of death. The median OS with divarasib was 17.7 months compared with 12.0 months with sotorasib and adagrasib. So, an absolute improvement in median OS of 5.7 months.
And the BICR-confirmed objective response rate (ORR) with divarasib was 58% compared with 32% in patients treated with sotorasib or adagrasib.
Divarasib also exhibited a manageable and, by many metrics, a favorable safety profile compared with sotorasib or adagrasib. There were fewer high-grade treatment-related adverse events, and there were fewer serious adverse events that were related to treatment in patients treated with divarasib. And this resulted in a lower treatment discontinuation rate due to treatment-related adverse events: only 4.8% in patients treated with divarasib compared with 11.7% in patients treated with sotorasib or adagrasib.
Overall, the Krascendo 1 clinical trial met both its primary endpoint of PFS by BICR, but also the key secondary endpoints of OS and BICR-confirmed ORR, with a manageable and by many metrics favorable safety profile. Based on the totality of the data, divarasib represents a new standard of care for previously treated patients with advanced or metastatic KRAS G12C-mutant NSCLC.
《肿瘤瞭望》:请您解读下该研究亚组分析的结果。在不同临床与分子特征的亚组中,Divarasib的获益一致性如何?您如何看待其在更广泛人群中的临床应用定位?
Ferdinandos Skoulidis教授:无论是PFS获益还是OS获益,Divarasib在绝大多数临床特征和分子特征定义的亚组中均保持了高度的一致性。从本次大会公布的森林图数据来看,涵盖不同性别、年龄、种族、地域以及不同治疗线数的患者,其风险比(HR)均全面倾向于Divarasib组。 例如,在二线治疗人群中(HR 0.54)与三线及以上人群中(HR 0.56),其获益幅度高度一致;在不同程序性死亡配体1(PD-L1)表达水平的患者中,也均观察到了显著改善。
特别值得关注的是,在几类传统意义上预后极差、治疗棘手的难治性亚组中,Divarasib依然展现出了稳健的疗效:
- 中枢神经系统(CNS)转移: 对于伴有CNS转移史的患者,Divarasib组的中位PFS为6.8个月(对照组5.7个月,HR 0.74);而在无CNS转移史的患者中,中位PFS达11.2个月(对照组5.4个月,HR 0.52)。尽管脑转移患者的获益幅度受疾病负荷影响较无脑转移者稍有减弱,但对比对照组依然维持了临床获益。
- 基线肝转移:伴有肝转移的患者往往预后不良,但在该亚组中,Divarasib对比对照组依然显示出显著的PFS获益(中位PFS 5.5个月 vs 3.0个月,HR 0.39),提示其对内脏转移患者具有确切的抗肿瘤活性。
- KEAP1共突变: KEAP1突变通常导致肿瘤微环境呈免疫抑制状态,且对第一代KRAS抑制剂及免疫治疗均不敏感。然而,在携带KEAP1突变的分子学不良预后亚组中,Divarasib依然维持了确切的临床获益(中位PFS 4.6个月 vs 2.8个月,HR 0.56);而在KEAP1未突变/未知人群中,中位PFS达到12.9个月(对照组6.7个月,HR 0.55)。
基于亚组分析结论,我认为Divarasib的获益覆盖了绝大多数患者亚群。这将促使其在KRAS G12C突变NSCLC患者群体中被广泛使用,而不受特定临床或分子特征的限制。当然,我们仍需开展更多转化研究,以深入了解和明确预测缓解与耐药的分子标志物。但目前可以说,Divarasib作为“同类最佳(Best-in-class)”的非活性状态(inactive-state)选择性KRAS G12C抑制剂,其在KRAS突变NSCLC人群中的广泛应用是毋庸置疑的。
Oncology Frontier: Could you elaborate on the subgroup analyses? How do you view the consistency of the PFS and OS benefits across different clinical and molecular subgroups, and the clinical positioning of divarasib in the broader patient population?
Prof. Ferdinandos Skoulidis: Both the PFS benefit with divarasib compared with sotorasib or adagrasib, and the OS benefit with divarasib, were broadly consistent across clinically and molecularly defined patient subgroups. So this included patients with a history of CNS metastasis. It also included patients with baseline liver metastasis, and it further included patients with KEAP1-mutated tumors, which we know represent a molecularly adverse subgroup of patients.
So the conclusion from the subgroup analysis is that the benefit of divarasib extends to most patient subgroups. And I really think that this will result in broad use of divarasib across the entire patient population of KRAS G12C-mutant NSCLC, regardless of clinical or molecular patient characteristics. More work needs to be done to understand and better define molecular predictors of response and resistance. But I think there is little doubt that divarasib represents the best-in-class inactive-state selective KRAS G12C inhibitor that will be broadly applied to the patient population with KRAS mutations in NSCLC.
《肿瘤瞭望》:请您谈谈关于KRAS G12C抑制剂的获得性耐药机制探索进展及未来的探索方向?
Ferdinandos Skoulidis教授:关于KRAS G12C抑制剂的获得性或适应性耐药模式,目前的研究主要将其分为三大类:第一类是基因组层面的耐药机制,涉及KRAS自身或RAS家族的其他成员(即靶点内耐药);也可能涉及MAPK通路其他组件的继发突变导致通路再激活,或是通过肿瘤细胞表面的多重受体酪氨酸激酶(RTK)发生旁路激活。第二类是适应性通路再激活,这通常由未突变的野生型RAS(Wild-Type RAS,包括野生型KRAS、HRAS或NRAS亚型)介导。第三类是部分患者发生的谱系转换,例如组织学转化。
然而,令人关注的是,在接受非活性状态选择性KRAS G12C抑制剂治疗后发生获得性耐药的患者中,约50%无法检测到明确的基因组耐药机制。正是针对这部分患者,我们需要更深入地探索药物耐受持久细胞中发生的全部分子适应谱系,因为这些细胞最终构成了适应性耐药产生的肿瘤细胞储备库。因此,未来必须开展更多研究以全面解析耐药机制,并开发更合理的联合治疗策略,以精准靶向特定的获得性耐药机制。
Oncology Frontier: What are the current understandings and future directions regarding the acquired resistance mechanisms to inactive-state selective KRAS G12C inhibitors?
Prof. Ferdinandos Skoulidis: Acquired or adaptive resistance patterns with KRAS G12C inhibitors have been explored for a number of off-state selective KRAS G12C inhibitors, and they broadly are divided into three groups.
So we've got genomic mechanisms of resistance that involve KRAS itself or other members of the RAS family. So this represents on-target resistance. You can have secondary mutations in other components of the MAP kinase pathway leading to pathway reactivation, or bypass, for example, involving multiple receptor tyrosine kinases on the surface of the tumor cell. It can also involve adaptive pathway reactivation that is frequently mediated via the wild-type RAS isoforms, KRAS, HRAS, or NRAS. Finally, a subset of patients that develop acquired resistance develop lineage shifts, such as histological transformation.
However, approximately 50% of patients with acquired resistance to inactive-state selective KRAS G12C inhibitors have no identifiable genomic mechanism of resistance. And it's really these patients where we need to dig deeper to try to understand the full spectrum of molecular adaptations that can occur in drug-tolerant persister cells, which ultimately represent the reservoir of tumor cells from which adaptive resistance will emerge. So more work needs to happen in order to understand the full spectrum of resistance mechanisms and the more rational combination therapeutic strategies to target individual mechanisms of acquired resistance.
《肿瘤瞭望》:本届ESMO大会上还有哪些胸部肿瘤领域的研究进展或热点让您印象最为深刻?哪些有潜力的疗法有望改变临床实践?
Ferdinandos Skoulidis教授:我必须承认我可能有些个人倾向,因为我坚信Krascendo 1的研究结果是具有改变临床实践意义的,并为经治KRAS G12C突变NSCLC确立了新标准。但同时,我也对DeLLphi-305临床研究的结果印象深刻,该研究评估了塔拉妥单抗(Tarlatamab)用于广泛期小细胞肺癌(ES-SCLC)的维持治疗。 这是另一项具有开创性的研究,为这种致命恶性肿瘤的治疗确立了新标准并带来了范式转变。
Oncology Frontier: Beyond your study, what other research advances or hot topics in the thoracic tumor field at this ESMO Congress impressed you the most, and which promising therapies have the potential to change clinical practice?
Prof. Ferdinandos Skoulidis: I am obviously slightly biased here because I believe that the Krascendo 1 clinical trial results are practice-changing and represent the new standard of care for patients with previously treated KRAS G12C-mutant NSCLC. But I was also very impressed with the results of the DeLLphi-305 clinical trial with maintenance tarlatamab in patients with extensive-stage small cell lung cancer. This is another groundbreaking study that has set a new standard of care and represents a paradigm shift in the treatment of this deadly malignancy. So I would highlight those two studies.
参考文献:
Ferdinandos Skoulidis, et al. Krascendo 1: Efficacy and safety of divarasib (diva) vs sotorasib (soto) or adagrasib (ada) in previously treated locally advanced or metastatic KRAS G12C-mutated NSCLC. 2026 ESMO. LBA5